Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Source: Science Source Mantle cell lymphoma is a rare disease. In the United States, the annual incidence is approximately 4 to 8 cases per 1 million people. This accounts for 3% to 10% of all ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

WASHINGTON - The U.S. Food and Drug Administration has granted approval to AstraZeneca (NASDAQ:AZN)'s Calquence (acalabrutinib), in combination with bendamustine and rituximab, for the treatment of ...

(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

A Shuswap woman who has endeavoured to support fellow survivors of child sexual abuse is now the focus of community giving.

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...